Finally! J_老虎社区_美港股上老虎

Pixiestars
2021-11-01

Finally! Just hope that they are able to manufacture the vaccines

Novavax stock surged 14.2% in premarket trading

Biotechnology company Novavax stock surged 14.2% in premarket trading after filing for authorization

Novavax stock surged 14.2% in premarket trading

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":849433164,"tweetId":"849433164","gmtCreate":1635772426367,"gmtModify":1635772426593,"author":{"id":3581832720375359,"idStr":"3581832720375359","authorId":3581832720375359,"authorIdStr":"3581832720375359","name":"Pixiestars","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":46,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Finally! Just hope that they are able to manufacture the vaccines</p></body></html>","htmlText":"<html><head></head><body><p>Finally! Just hope that they are able to manufacture the vaccines</p></body></html>","text":"Finally! Just hope that they are able to manufacture the vaccines","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/849433164","repostId":1118499473,"repostType":4,"repost":{"id":"1118499473","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635764611,"share":"https://www.laohu8.com/m/news/1118499473?lang=&edition=full","pubTime":"2021-11-01 19:03","market":"us","language":"en","title":"Novavax stock surged 14.2% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1118499473","media":"Tiger Newspress","summary":"Biotechnology company Novavax stock surged 14.2% in premarket trading after filing for authorization","content":"<p>Biotechnology company Novavax stock surged 14.2% in premarket trading&nbsp;after filing for authorization of its COVID-19 vaccine in multiple countries and regions.</p>\n<p><img src=\"https://static.tigerbbs.com/1f507bc8048dfc7207968fa1251226ef\" tg-width=\"849\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<p>Novavax,&nbsp;Inc.&nbsp;today announced the completion of its rolling submission to Health Canada for authorization of its COVID-19 vaccine candidate, the first filing of a protein-based COVID-19 vaccine inCanada. In addition, the company has completed the submission of all data and modules to the European Medicines Agency (EMA) to support the final regulatory review of its dossier.</p>\n<p>In addition,Novavax&nbsp;have&nbsp;announced the completion of its rolling regulatory submission to the U.K.;</p>\n<p>Novavax has announced that it has already completed its rolling submission to the Therapeutic Goods Administration (TGA) in Australia for provisional approval of its COVID-19 vaccine candidate.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax stock surged 14.2% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax stock surged 14.2% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-01 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biotechnology company Novavax stock surged 14.2% in premarket trading&nbsp;after filing for authorization of its COVID-19 vaccine in multiple countries and regions.</p>\n<p><img src=\"https://static.tigerbbs.com/1f507bc8048dfc7207968fa1251226ef\" tg-width=\"849\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<p>Novavax,&nbsp;Inc.&nbsp;today announced the completion of its rolling submission to Health Canada for authorization of its COVID-19 vaccine candidate, the first filing of a protein-based COVID-19 vaccine inCanada. In addition, the company has completed the submission of all data and modules to the European Medicines Agency (EMA) to support the final regulatory review of its dossier.</p>\n<p>In addition,Novavax&nbsp;have&nbsp;announced the completion of its rolling regulatory submission to the U.K.;</p>\n<p>Novavax has announced that it has already completed its rolling submission to the Therapeutic Goods Administration (TGA) in Australia for provisional approval of its COVID-19 vaccine candidate.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118499473","content_text":"Biotechnology company Novavax stock surged 14.2% in premarket trading after filing for authorization of its COVID-19 vaccine in multiple countries and regions.\n\nNovavax, Inc. today announced the completion of its rolling submission to Health Canada for authorization of its COVID-19 vaccine candidate, the first filing of a protein-based COVID-19 vaccine inCanada. In addition, the company has completed the submission of all data and modules to the European Medicines Agency (EMA) to support the final regulatory review of its dossier.\nIn addition,Novavax have announced the completion of its rolling regulatory submission to the U.K.;\nNovavax has announced that it has already completed its rolling submission to the Therapeutic Goods Administration (TGA) in Australia for provisional approval of its COVID-19 vaccine candidate.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1266,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["JE"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":55,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}